Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Sep 30, 2025 | (Q6)Mar 31, 2025 | (FY)Sep 30, 2024 | (Q6)Mar 31, 2024 | (FY)Sep 30, 2023 | (Q6)Mar 31, 2023 | (FY)Sep 30, 2022 | (Q6)Mar 31, 2022 | (FY)Sep 30, 2021 | (Q6)Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 5.86%152.39M | 13.94%85.54M | -18.86%143.96M | -30.25%75.08M | 60.84%177.42M | 20.75%107.64M | -50.55%110.31M | 14.92%89.14M | -26.60%223.08M | -50.88%77.57M |
| Operating income | 5.86%152.39M | 13.94%85.54M | -18.86%143.96M | -30.25%75.08M | 60.84%177.42M | 20.75%107.64M | -50.55%110.31M | 14.92%89.14M | -26.60%223.08M | -50.88%77.57M |
| Cost of sales | -4.91%-140.65M | -17.71%-81.84M | 8.78%-134.07M | 21.71%-69.53M | 25.52%-146.97M | 12.11%-88.81M | 2.41%-197.33M | 7.51%-101.05M | 24.52%-202.2M | 8.55%-109.25M |
| Operating expenses | -4.91%-140.65M | -17.71%-81.84M | 8.78%-134.07M | 21.71%-69.53M | 25.52%-146.97M | 12.11%-88.81M | 2.41%-197.33M | 7.51%-101.05M | 24.52%-202.2M | 8.55%-109.25M |
| Gross profit | 18.73%11.74M | -33.34%3.7M | -67.52%9.89M | -70.56%5.54M | 134.99%30.45M | 258.10%18.83M | -516.79%-87.02M | 62.42%-11.91M | -42.05%20.88M | -182.37%-31.69M |
| Administrative expenses | 20.76%-26.38M | 11.05%-12.58M | -14.06%-33.29M | 60.63%-14.14M | 45.94%-29.18M | -26.32%-35.92M | -25.06%-53.98M | -17.18%-28.44M | -44.35%-43.16M | -53.41%-24.27M |
| Impairment and provision | 1,534.78%1.65M | 340.00%836K | 92.99%-115K | 238.69%190K | 50.65%-1.64M | -123.30%-137K | 30.84%-3.32M | -37.91%588K | -3,596.15%-4.81M | 544.60%947K |
| -Other impairment is provision | 1,534.78%1.65M | 340.00%836K | 92.99%-115K | 238.69%190K | 50.65%-1.64M | -123.30%-137K | 30.84%-3.32M | -37.91%588K | -3,596.15%-4.81M | 544.60%947K |
| Special items of operating profit | 232.11%1.18M | 718.44%1.15M | -49.93%355K | -98.11%141K | -87.16%709K | 191.61%7.47M | 113.83%5.52M | 22.23%2.56M | -50.66%2.58M | -3.41%2.1M |
| Operating profit | 49.02%-11.8M | 16.62%-6.89M | -7,011.94%-23.16M | 15.31%-8.27M | 100.24%335K | 73.75%-9.76M | -466.35%-138.8M | 29.70%-37.2M | -318.21%-24.51M | -315.05%-52.91M |
| Financing cost | 18.05%-168K | 35.19%-70K | 0.49%-205K | 79.07%-108K | 30.41%-206K | -111.48%-516K | 14.45%-296K | 41.06%-244K | -13.07%-346K | -225.98%-414K |
| Earning before tax | 48.75%-11.97M | 16.86%-6.96M | -18,208.53%-23.36M | 18.51%-8.38M | 100.09%129K | 72.55%-10.28M | -459.66%-139.09M | 29.79%-37.44M | -327.49%-24.85M | -317.86%-53.33M |
| Tax | ---- | ---- | ---- | ---- | ---- | -16.67%-14K | -86.20%138K | -118.18%-12K | 236.61%1M | 102.14%66K |
| After-tax profit from continuing operations | 48.75%-11.97M | 16.86%-6.96M | -18,208.53%-23.36M | 18.62%-8.38M | 100.09%129K | 72.52%-10.29M | -482.54%-138.95M | 29.68%-37.45M | -334.01%-23.85M | -348.98%-53.26M |
| After-tax profit from non-continuing business | ---- | ---- | 586.01%13.31M | ---8.3M | ---2.74M | ---- | ---- | ---- | ---- | ---- |
| Earning after tax | -19.09%-11.97M | 58.23%-6.96M | -285.32%-10.05M | -61.99%-16.67M | 98.12%-2.61M | 72.52%-10.29M | -482.54%-138.95M | 29.68%-37.45M | -334.01%-23.85M | -348.98%-53.26M |
| Minority shareholders should account for non-continuing business profits | ---- | ---- | 102.02%17K | --211K | ---840K | ---- | ---- | ---- | ---- | ---- |
| Minority profit | ---- | ---- | 102.02%17K | 10.47%211K | 73.48%-840K | 120.15%191K | -22.80%-3.17M | 40.71%-948K | -2,333.02%-2.58M | ---1.6M |
| Shareholders should account for profits from continuing business | 48.75%-11.97M | 16.86%-6.96M | -18,208.53%-23.36M | ---8.38M | --129K | ---- | ---- | ---- | ---- | ---- |
| Shareholders should account for profits from non-continuing business | ---- | ---- | 800.21%13.29M | ---8.51M | ---1.9M | ---- | ---- | ---- | ---- | ---- |
| Profit attributable to shareholders | -18.89%-11.97M | 58.76%-6.96M | -469.25%-10.07M | -61.05%-16.89M | 98.70%-1.77M | 71.28%-10.48M | -538.28%-135.79M | 29.34%-36.51M | -306.56%-21.27M | -341.50%-51.66M |
| Basic earnings per share | -19.05%-0.015 | 58.77%-0.0087 | -472.73%-0.0126 | -61.07%-0.0211 | 98.70%-0.0022 | 71.27%-0.0131 | -537.97%-0.1697 | 29.41%-0.0456 | -306.20%-0.0266 | -341.95%-0.0646 |
| Diluted earnings per share | -19.05%-0.015 | 58.77%-0.0087 | -472.73%-0.0126 | -61.07%-0.0211 | 98.70%-0.0022 | 71.27%-0.0131 | -537.97%-0.1697 | 29.41%-0.0456 | -306.20%-0.0266 | -341.95%-0.0646 |
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
| Auditor | -- | -- | National Health Accounting Firm Limited | -- | National Health Accounting Firm Limited | -- | National Health Accounting Firm Limited | -- | Guowei Certified Public Accountants Co., Ltd. | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.